Most Active Stocks
Follow the most active stocks today, including share price changes, trading volume, and more. We cover the most traded stocks with daily market data, news, and analysis from our Foolish experts, helping you make informed investing decisions.
Related Articles
Featured Article
3 Things You Need to Know if You Buy Pfizer Today
Reuben Gregg Brewer
|
Oct 2, 2025
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it.
This Is Opendoor's Biggest Risk (Hint: It's Not the Housing Market)
David Jagielski
|
Oct 2, 2025
Although Opendoor grew its sales last quarter, its gross profit declined.
3 Blue Chip Stocks That Have Soared 380% (and Higher) Over the Past 5 Years
David Jagielski
|
Oct 2, 2025
By investing in quality growth stocks, you can put yourself in an excellent position to earn a great return.
Which U.S. Companies Are Poised to Profit From Reshoring Supply Chains?
Jeremy Bowman
|
Oct 2, 2025
New tariffs are quickly rearranging supply chains.
Could Buying QuantumScape Stock Today Set You Up for Life?
Leo Sun
|
Oct 2, 2025
The solid-state battery maker is still a speculative and divisive investment.
Here's the Secret Weapon That Will Boost Tesla's EV Business
Lee Samaha
|
Oct 2, 2025
The future approval of publicly available unsupervised FSD will strengthen Elon Musk's company in many ways.
History Suggests 1 Trillion-Dollar Artificial Intelligence (AI) Stock Makes for a No-Brainer Buy, While Another Is Treading in Dangerous Territory
Sean Williams
|
Oct 2, 2025
Although history doesn't repeat to a "t" on Wall Street, it does have a tendency to rhyme.
Why Pfizer Stock Trounced the Market Today
Eric Volkman
|
Oct 1, 2025
A bullish analyst note added to the generally good sentiment on the company.
Why QuantumScape Stock Jumped Over 15% Today
Neha Chamaria
|
Oct 1, 2025
QuantumScape stock has more than doubled in three months. Its latest partnership is adding fuel to the fire.
Pfizer Just Announced a Massive Deal with TrumpRx. Here's What Investors Need to Know
Keith Speights
|
Oct 1, 2025
Pfizer's CEO says the deal with the Trump administration is "a win" for the company. He's probably right.
View More Articles